Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Combined Modality Therapy
100%
Carboplatin
100%
Paclitaxel
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Thoracic Radiation
100%
Combined Modality
80%
Phase II Trial
60%
Chemotherapy
40%
Combination Chemotherapy
40%
Resectable Lung Cancer
40%
Carboplatin-paclitaxel
40%
Locally Advanced
40%
Meta-analysis
20%
Non-small Cell Lung Cancer (NSCLC)
20%
Randomized Trial
20%
Failure Pattern
20%
Treatment Options
20%
Taxol
20%
Survival Benefit
20%
Optimal Management
20%
Princeton
20%
Bristol-Myers Squibb
20%
Docetaxel
20%
Platinum Compounds
20%
Novel Agents
20%
Local Control
20%
Multimodality
20%
Platinum-based
20%
Systemic Disease
20%
Thoracic Radiation Therapy
20%
Distant Control
20%
Hyperfractionated
20%
Multidisciplinary Approach
20%
Gemcitabine
20%
Vinorelbine
20%
Multi-center Randomized Study
20%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Carboplatin
100%
Paclitaxel
100%
Multimodality Cancer Therapy
100%
Disease
16%
Meta-Analysis
16%
Radiation Therapy
16%
Combination Chemotherapy
16%
Hope
16%
Gemcitabine
16%
Systemic Disease
16%
Vinorelbine
16%
Docetaxel
16%
Platinum Derivative
16%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Carboplatin
100%
Paclitaxel
100%
Chemotherapy
66%
Disease
16%
Gemcitabine
16%
Platinum Derivative
16%
Docetaxel
16%
Systemic Disease
16%
Vinorelbine
16%